Lobeline

Central respiratory depression is a high-risk acute emergency in scenarios such as clinical anesthesia, neonatal asphyxia, and central nervous system drug poisoning. Rapid reversal of respiratory failure is the core goal of treatment. Lobeline is an active pharmaceutical ingredient (API) belonging to the category of respiratory stimulants. It stimulates the chemoreceptors of the carotid sinus and aortic body to reflexively excite the medullary respiratory center, and does not directly act on the central nervous system. Therefore, it has a mild onset effect, higher safety, and is less likely to cause adverse reactions such as convulsions or overexcitation. It is mainly used clinically for neonatal asphyxia, respiratory depression caused by carbon monoxide poisoning, respiratory failure caused by diseases such as opioid poisoning and pneumonia, and is a standing first-aid medication in emergency departments, anesthesiology departments and pediatrics departments.

The global lobeline market size is stable at around USD 230 million, with a compound annual growth rate of approximately 3.2% in the past five years. The growth momentum mainly comes from the improvement of the first-aid system in primary medical institutions and the enhancement of neonatal treatment capacity in developing countries. In the domestic market, lobeline is a Class A variety of the national medical insurance, and is also included in the first-aid drug catalog, with relatively rigid clinical demand. At present, the localization rate has exceeded 90%, and only a small number of high-end preparations still rely on imported raw materials. The overall supply pattern is stable, and there is no obvious risk of supply shortage.

The original research enterprise of lobeline is Mylan N.V., and the original research trade name is Lobeline Hydrochloride Injection. Its core compound patent expired globally in 1980. At present, the mainstream marketed dosage form is injection, with specifications including 1ml:3mg and 1ml:10mg. The original research preparation has been included in the FDA Reference Listed Drug (RLD) catalog. The original research preparation is not imported into China, and the reference listed drugs of domestic preparations are mostly the same varieties produced by domestic enterprises. Up to now, 12 domestic enterprises have obtained A status for their lobeline API through CDE registration, and another 3 enterprises have registration applications under evaluation. There are a total of 37 domestic preparation approvals, which can fully meet the domestic clinical use demand. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for lobeline API. Most of the products are in stock. In-stock products ordered before 16:00 will be shipped on the same day. They comply with multiple regulatory requirements such as the Chinese Pharmacopoeia and FDA, and can effectively help pharmaceutical enterprises complete API quality research, generic drug consistency evaluation and declaration work, and fully meet the quality control needs of the whole process of R&D and production.